Activist investor discloses 17% stake in Acorda, urges sale
August 08, 2017
Therapeutic Devices | Ardsley, NY
Scopia Capital Management has filed a letter with the SEC urging neurological drug developer Acorda Therapeutics to form a committee to explore a sale, citing Acorda's defeat in March in a patent dispute regarding a multiple sclerosis treatment. Scopia has amassed a 17% stake in the business. Shares of Acorda (NASDAQ: ACOR) gained nearly 4% Monday.